The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

Citation

SOMMEIJER, D, Karapetis, C, Zalcberg, J et al. 2014, 'The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17', Acta Oncologica, vol. 53, no. 7, pp. 877-884.

Year

2014

ANU Authors

Updated:  03 February 2023 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers